9 results on '"Ching-Chih Lin"'
Search Results
2. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
- Author
-
Po‐Yao Hsu, Tzu‐Sheng Cheng, Shih‐Chang Chuang, Wen‐Tsan Chang, Po‐Cheng Liang, Cheng‐Ting Hsu, Yu‐Ju Wei, Tyng‐Yuan Jang, Ming‐Lun Yeh, Ching‐I Huang, Yi‐Hung Lin, Chih‐Wen Wang, Ming‐Yen Hsieh, Nai‐Jen Hou, Meng‐Hsuan Hsieh, Yi‐Shan Tsai, Yu‐Min Ko, Ching‐Chih Lin, Kuan‐Yu Chen, Chia‐Yen Dai, Zu‐Yau Lin, Shinn‐Cherng Chen, Jee‐Fu Huang, Wan‐Long Chuang, Chung‐Feng Huang, and Ming‐Lung Yu
- Subjects
efficacy ,hepatocellular carcinoma ,regorafenib ,sorafenib ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background and Aims Regorafenib has demonstrated its survival benefit for unresectable hepatocellular carcinoma (uHCC) patients in a phase III clinical trial. We aimed to assess the efficacy and tolerability of regorafenib and the predictors of treatment outcomes in Taiwanese patients. Methods We analyzed the survival, best overall response, predictors of treatment outcomes, and safety for uHCC patients who had tumor progression on sorafenib therapy and received regorafenib as salvage therapy between March 2018 and November 2020. Results Eighty‐six patients with uHCC were enrolled (median age, 66.5 years; 76.7% male). The median regorafenib treatment duration was 4.0 months (95% confidence interval [CI], 3.6–4.6). The most frequently reported adverse events were hand‐foot skin reaction (44.2%), diarrhea (36.0%), and fatigue (29.1%). No unpredictable toxicity was observed during treatment. The median overall survival (OS) with regorafenib was 12.4 months (95% CI, 7.8–17.0) and the median progression‐free survival (PFS) was 4.2 months (95% CI, 3.7–4.7). Of 82 patients with regorafenib responses assessable, 4 patients (4.9%) achieved a partial response, and 33 (40.2%) had stable disease, leading to a disease control rate (DCR) of 45.1% (n = 37). Patients possessing baseline AFP 10% reduction at 4 weeks or >20% reduction at 8 weeks after regorafenib administration) exhibited comparable treatment outcomes to those with baseline AFP
- Published
- 2022
- Full Text
- View/download PDF
3. Metabolomic Analysis Demonstrates the Impacts of Polyketide Synthases PKS14 and PKS15 on the Production of Beauvericins, Bassianolide, Enniatin A, and Ferricrocin in Entomopathogen Beauveria bassiana
- Author
-
Wachiraporn Toopaang, Kullyanee Panyawicha, Chettida Srisuksam, Wei-Chen Hsu, Ching-Chih Lin, Morakot Tanticharoen, Yu-Liang Yang, and Alongkorn Amnuaykanjanasin
- Subjects
Beauveria bassiana ,polyketide synthase ,nonribosomal peptides ,GNPS ,molecular networking ,Microbiology ,QR1-502 - Abstract
Beauveria bassiana is a globally distributed entomopathogenic fungus that produces various secondary metabolites to support its pathogenesis in insects. Two polyketide synthase genes, pks14 and pks15, are highly conserved in entomopathogenic fungi and are important for insect virulence. However, understanding of their mechanisms in insect pathogenicity is still limited. Here, we overexpressed these two genes in B. bassiana and compared the metabolite profiles of pks14 and pks15 overexpression strains to those of their respective knockout strains in culture and in vivo using tandem liquid chromatography-mass spectrometry (LC-MS/MS) with Global Natural Products Social Molecular Networking (GNPS). The pks14 and pks15 clusters exhibited crosstalk with biosynthetic clusters encoding insect-virulent metabolites, including beauvericins, bassianolide, enniatin A, and the intracellular siderophore ferricrocin under certain conditions. These secondary metabolites were upregulated in the pks14-overexpressing strain in culture and the pks15-overexpressing strain in vivo. These data suggest that pks14 and pks15, their proteins or their cluster components might be directly or indirectly associated with key pathways in insect pathogenesis of B. bassiana, particularly those related to secondary metabolism. Information about interactions between the polyketide clusters and other biosynthetic clusters improves scientific understanding about crosstalk among biosynthetic pathways and mechanisms of pathogenesis.
- Published
- 2023
- Full Text
- View/download PDF
4. Deep Learning Applied to Defect Detection in Powder Spreading Process of Magnetic Material Additive Manufacturing
- Author
-
Hsin-Yu Chen, Ching-Chih Lin, Ming-Huwi Horng, Lien-Kai Chang, Jian-Han Hsu, Tsung-Wei Chang, Jhih-Chen Hung, Rong-Mao Lee, and Mi-Ching Tsai
- Subjects
convolution neural network ,metal additive manufacturing ,powder-spreading defect ,selective laser melting ,Technology ,Electrical engineering. Electronics. Nuclear engineering ,TK1-9971 ,Engineering (General). Civil engineering (General) ,TA1-2040 ,Microscopy ,QH201-278.5 ,Descriptive and experimental mechanics ,QC120-168.85 - Abstract
Due to its advantages of high customization and rapid production, metal laser melting manufacturing (MAM) has been widely applied in the medical industry, manufacturing, aerospace and boutique industries in recent years. However, defects during the selective laser melting (SLM) manufacturing process can result from thermal stress or hardware failure during the selective laser melting (SLM) manufacturing process. To improve the product’s quality, the use of defect detection during manufacturing is necessary. This study uses the process images recorded by powder bed fusion equipment to develop a detection method, which is based on the convolutional neural network. This uses three powder-spreading defect types: powder uneven, powder uncovered and recoater scratches. This study uses a two-stage convolutional neural network (CNN) model to finish the detection and segmentation of defects. The first stage uses the EfficientNet B7 to classify the images with/without defects, and then to locate the defects by evaluating three different instance segmentation networks in second stage. Experimental results show that the accuracy and Dice measurement of Mask-R-CNN network with ResNet 152 backbone can reach 0.9272 and 0.9438. The computational time of an image only takes approximately 0.2197 sec. The used CNN model meets the requirements of the early detected defects, regarding the SLM manufacturing process.
- Published
- 2022
- Full Text
- View/download PDF
5. Exploring the relationship between metabolite composition and the cold/hot properties ascribed in traditional Chinese medicine by mass spectral molecular networking–a pilot study
- Author
-
Chun-Han Su, Yu-Chieh Cheng, Kuei-Hung Lai, Yu-Chia Chang, Chi-Hui Sun, Po-Wen Tu, Ching-Chih Lin, Tsong-Long Hwang, and Yu-Liang Yang
- Subjects
Pharmacology ,Food Science - Published
- 2022
6. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison
- Author
-
Chun-Ting Chen, Ming-Ying Lu, Meng-Hsuan Hsieh, Pei-Chien Tsai, Tsai-Yuan Hsieh, Ming-Lun Yeh, Ching-I Huang, Yi-Shan Tsai, Yu-Min Ko, Ching-Chih Lin, Kuan-Yu Chen, Yu-Ju Wei, Po-Yao Hsu, Cheng-Ting Hsu, Tyng-Yuan Jang, Ta-Wei Liu, Po-Cheng Liang, Ming-Yen Hsieh, Zu-Yau Lin, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Yu-Lueng Shih, and Ming-Lung Yu
- Subjects
Universal screen ,Gastroenterology ,virus diseases ,General Medicine ,Hepacivirus ,Hepatitis C, Chronic ,Direct-acting antivirals ,Antiviral Agents ,Hepatitis C ,Prisons ,Prospective Study ,Humans ,Sofosbuvir ,People who inject drugs ,Velpatasvir - Abstract
BACKGROUND Prisoners are at risk of hepatitis C virus (HCV) infection, especially among the people who inject drugs (PWID). We implemented an outreach strategy in combination with universal mass screening and immediate onsite treatment with a simplified pan-genotypic direct-acting antivirals (DAA) regimen, 12 wk of sofosbuvir/velpatasvir, in a PWID-dominant prison in Taiwan. AIM To implement an outreach strategy in combination with universal mass screening and immediate onsite treatment with a simplified pan-genotypic DAA regimen in a PWID-dominant prison in Taiwan. METHODS HCV-viremic patients were recruited for onsite treatment program for HCV micro-elimination with a pangenotypic DAA regimen, 12 wk of sofosbuvir/ velpatasvir, from two cohorts in Penghu Prison, either identified by mass screen or in outpatient clinics, in September 2019. Another group of HCV-viremic patients identified sporadically in outpatient clinics before mass screening were enrolled as a control group. The primary endpoint was sustained virological response (SVR12, defined as undetectable HCV ribonucleic acid (RNA) 12 wk after end-of-treatment). RESULTS A total of 212 HCV-viremic subjects were recruited for HCV micro-elimination campaign; 91 patients treated with sofosbuvir/Ledipasvir or glecaprevir/ pibrentasvir before mass screening were enrolled as a control. The HCV micro-elimination group had significantly lower proportion of diabetes, hypertension, hyperlipidemia, advanced fibrosis and chronic kidney diseases, but higher levels of HCV RNA. The SVR12 rate was comparable between the HCV micro-elimination and control groups, 95.8% (203/212) vs 94.5% (86/91), respectively, in intent-to-treat analysis, and 100% (203/203) vs 98.9% (86/87), respectively, in per-protocol analysis. There was no virological failure, treatment discontinuation, and serious adverse event among sofosbuvir/velpatasvir-treated patients in the HCV micro-elimination group. CONCLUSION Outreach mass screening followed by immediate onsite treatment with a simplified pangenotypic DAA regimen, sofosbuvir/velpatasvir, provides successful strategies toward HCV micro-elimination among prisoners.
- Published
- 2022
7. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication
- Author
-
Ming-Ying Lu, Ming-Lun Yeh, Ching-I Huang, Shu-Chi Wang, Yi-Shan Tsai, Pei-Chien Tsai, Yu-Min Ko, Ching-Chih Lin, Kuan-Yu Chen, Yu-Ju Wei, Po-Yao Hsu, Cheng-Ting Hsu, Tyng-Yuan Jang, Ta-Wei Liu, Po-Cheng Liang, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, and Ming-Lung Yu
- Subjects
Sustained virologic response ,Carcinoma, Hepatocellular ,Hepatitis C virus ,Hepatocellular carcinoma ,Tumor Necrosis Factor-alpha ,Liver Neoplasms ,Gastroenterology ,General Medicine ,Hepacivirus ,Hepatitis C, Chronic ,Antiviral Agents ,digestive system diseases ,Tumor necrosis factor-α ,Risk Factors ,Retrospective Cohort Study ,Cytokines ,Humans ,Cytokine ,Tumor necrosis factor-like weak inducer of apoptosis - Abstract
BACKGROUND Chronic hepatitis C virus (HCV) infection induces profound alterations in the cytokine and chemokine signatures in peripheral blood. Clearance of HCV by antivirals results in host immune modification, which may interfere with immune-mediated cancer surveillance. Identifying HCV patients who remain at risk of hepatocellular carcinoma (HCC) following HCV eradication remains an unmet need. We hypothesized that antiviral therapy-induced immune reconstruction may be relevant to HCC development. AIM To investigate the impact of differential dynamics of cytokine expression on the development of HCC following successful antiviral therapy. METHODS One hundred treatment-naïve HCV patients with advanced fibrosis (F3/4) treated with direct-acting antivirals (DAAs) or peginterferon/ribavirin who achieved sustained virologic response [SVR, defined as undetectable HCV RNA throughout 12 wk (SVR12) for the DAA group or 24 wk (SVR24) for the interferon group after completion of antiviral therapy] were enrolled since 2003. The primary endpoint was the development of new-onset HCC. Standard HCC surveillance (abdominal ultrasound and α-fetoprotein) was performed every six months during the follow-up. Overall, 64 serum cytokines were detected by the multiplex immunoassay at baseline and 24 wk after end-of-treatment. RESULTS HCC developed in 12 of the 97 patients over 459 person-years after HCV eradication. In univariate analysis, the Fibrosis-4 index (FIB-4), hemoglobin A1c (HbA1c), the dynamics of tumor necrosis factor-α (TNF-α), and TNF-like weak inducer of apoptosis (TWEAK) after antiviral therapy were significant HCC predictors. The multivariate Cox regression model showed that ΔTNF-α (≤ -5.7 pg/mL) was the most important risk factor for HCC (HR = 11.54, 95%CI: 2.27-58.72, P = 0.003 in overall cases; HR = 9.98, 95%CI: 1.88-52.87, P = 0.007 in the interferon group). An HCC predictive model comprising FIB-4, HbA1c, ΔTNF-α, and ΔTWEAK had excellent performance, with 3-, 5-, 10-, and 13-year areas under the curve of 0.882, 0.864, 0.903, and 1.000, respectively. The 5-year accumulative risks of HCC were 0%, 16.9%, and 40.0% in the low-, intermediate-, and high-risk groups, respectively. CONCLUSION Downregulation of serum TNF-α significantly increases the risk of HCC after HCV eradication. A predictive model consisting of cytokine kinetics could ameliorate personalized HCC surveillance strategies for post-SVR HCV patients.
- Published
- 2022
8. Graphitic carbon nitride embedded with single-atom Pt for photo-enhanced electrocatalytic hydrogen evolution reaction
- Author
-
En-Jing Lin, Yu-Bin Huang, Po-Kai Chen, Je-Wei Chang, Shu-Yi Chang, Wei-Ting Ou, Ching-Chih Lin, Yu-Hsien Wu, Jeng-Lung Chen, Chi Wen Pao, Chun-Jen Su, Chia-Hsin Wang, U-Ser Jeng, and Ying-Huang Lai
- Subjects
History ,Polymers and Plastics ,General Physics and Astronomy ,Surfaces and Interfaces ,General Chemistry ,Business and International Management ,Condensed Matter Physics ,Industrial and Manufacturing Engineering ,Surfaces, Coatings and Films - Published
- 2023
9. Exploring the relationship between metabolite composition and the cold/hot properties ascribed in traditional Chinese medicine by mass spectral molecular networking e A pilot study.
- Author
-
Chun-Han Su, Yu-Chieh Cheng, Kuei-Hung Lai, Yu-Chia Chang, Chi-Hui Sun, Po-Wen Tu, Ching-Chih Lin, Tsong-Long Hwang, and Yu-Liang Yang
- Subjects
- *
PILOT projects , *STATISTICS , *FLAVONOIDS , *METABOLOMICS , *LIQUID chromatography , *MOLECULAR biology , *MASS spectrometry , *DATA analysis , *CHINESE medicine , *METABOLITES - Abstract
Traditional Chinese medicine (TCM) has been applied to improve human health for millennia. In the TCM system, "medicinal property" ( yao xing; hot and cold properties) is a core concept used to describe the influences of medicinal materials on human physiological conditions, and metabolites are believed to be one of the major ingredients of TCMs that affect their medicinal property. However, due to a lack of comprehensive analyses of TCM metabolomes, information about the relationships between TCM metabolite composition and medicinal property remains limited. In this pilot study, a mass spectral molecular networking-based platform was established and applied to systematically profile the metabolome of 24 TCMs with various medicinal properties. The molecular networks were built based on the liquid chromatography-tandem mass spectrometry (LC-MS/MS) data from 50% EtOH extracts of 24 TCMs. The results showed that various classes of metabolites were clustered in the molecular networks, and the potential medicinal propertyassociated molecular families were filtered by screening the medicinal property and the diversity of TCM sources. For example, some specific types of flavonoids were identified in the representative cold-property (han xing) molecular families. In contrast, due to the limited sample size, the representative and universal hot-property (re xing) molecular family has not been well revealed. In summary, this study provides methodology and information on the potential relationships between the metabolite composition and the concept of medicinal property in TCM. Furthermore, the results can serve as a foundation for mass spectral molecular networking-based analysis of TCM metabolomes, facilitating TCM research and development. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.